Our Science

CAR T-cell therapy has shown remarkable success in some blood cancers, but it has struggled to work in solid tumours. Solid tumours are harder to safely target, actively suppress the immune system, and T cells struggle to last long enough in the body to fully clear the cancer.

At ImmunoKey, we are developing a next-generation CAR T-cell platform designed specifically to overcome these challenges.

A Three Part Solution

Our approach brings together three complementary research programmes, each addressing a key barrier that has limited existing therapies.

CARKey™ - Smarter Targeting
Recognition of multiple tumour markers whilst only fully activating inside the tumour. This makes it harder for cancer to escape and helps protect healthy tissue.

ReviT™ - Staying Active in the Tumour
Solid tumours send signals that switch immune cells off. ReviT helps CAR T cells resist these suppressive signals so they can keep working where they are needed most.

AmpliT™ - Longer-Lasting Effect
Even effective T cells can fade too quickly. AmpliT is designed to help CAR T cells last longer and remain active, increasing the chance of a durable response.

Built for Solid Tumours

Together, these programmes form a modular platform that can be adapted to different cancers. Our first focus is ovarian cancer, where there is significant unmet need, with the potential to expand into other solid tumours over time.

Our goal is simple: to make CAR T-cell therapy effective against solid tumours and bring new hope to patients with limited treatment options.